151 related articles for article (PubMed ID: 26135933)
21. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
[TBL] [Abstract][Full Text] [Related]
22. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
[TBL] [Abstract][Full Text] [Related]
23. Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt.
Matei DV; Renne G; Pimentel M; Sandri MT; Zorzino L; Botteri E; De Cicco C; Musi G; Brescia A; Mazzoleni F; Tringali V; Detti S; de Cobelli O
Clin Genitourin Cancer; 2012 Sep; 10(3):164-73. PubMed ID: 22401754
[TBL] [Abstract][Full Text] [Related]
24. Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy.
Lee JL; Eun Kim J; Ahn JH; Lee DH; Lee J; Kim CS; Hyuk Hong J; Hong B; Song C; Ahn H
Am J Clin Oncol; 2011 Apr; 34(2):140-4. PubMed ID: 20686407
[TBL] [Abstract][Full Text] [Related]
25. Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival.
Niedworok C; Tschirdewahn S; Reis H; Lehmann N; Szücs M; Nyirády P; Romics I; Rübben H; Szarvas T
Pathol Oncol Res; 2017 Jul; 23(3):643-650. PubMed ID: 28012116
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
27. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.
Kikuno N; Urakami S; Nakamura S; Hiraoka T; Hyuga T; Arichi N; Wake K; Sumura M; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M
Eur Urol; 2007 May; 51(5):1252-8. PubMed ID: 17208356
[TBL] [Abstract][Full Text] [Related]
28. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
Ploussard G; Terry S; Maillé P; Allory Y; Sirab N; Kheuang L; Soyeux P; Nicolaiew N; Coppolani E; Paule B; Salomon L; Culine S; Buttyan R; Vacherot F; de la Taille A
Cancer Res; 2010 Nov; 70(22):9253-64. PubMed ID: 21045157
[TBL] [Abstract][Full Text] [Related]
29. Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy.
Hirano D; Hasegawa R; Satoh K; Mochida J; Yamanaka Y; Hirakata H; Yamaguchi K; Sugimoto S; Kawata N; Takahashi S
Scand J Urol; 2014 Oct; 48(5):436-44. PubMed ID: 24730473
[TBL] [Abstract][Full Text] [Related]
30. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
[TBL] [Abstract][Full Text] [Related]
32. Chromogranin A staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy.
Krauss DJ; Amin M; Stone B; Ye H; Hayek S; Cotant M; Hafron J; Brabbins DS
Prostate; 2014 May; 74(5):520-7. PubMed ID: 24375481
[TBL] [Abstract][Full Text] [Related]
33. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
Cerulli C; Sciarra A; Salvatori G; Di Silverio F
Urology; 2004 Dec; 64(6):1231.e1-3. PubMed ID: 15596212
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.
Regan MM; O'Donnell EK; Kelly WK; Halabi S; Berry W; Urakami S; Kikuno N; Oh WK
Ann Oncol; 2010 Feb; 21(2):312-318. PubMed ID: 19633053
[TBL] [Abstract][Full Text] [Related]
35. Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
Sella A; Sternberg C; Kovel S; Yarom N; Skoneczna I
BJU Int; 2007 Sep; 100(3):533-5. PubMed ID: 17559560
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
Taplin ME; Xie W; Bubley GJ; Ernstoff MS; Walsh W; Morganstern DE; Regan MM
J Clin Oncol; 2006 Dec; 24(34):5408-13. PubMed ID: 17135641
[TBL] [Abstract][Full Text] [Related]
37. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
[TBL] [Abstract][Full Text] [Related]
38. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
[TBL] [Abstract][Full Text] [Related]
40. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Mahammedi H; Planchat E; Pouget M; Durando X; Curé H; Guy L; Van-Praagh I; Savareux L; Atger M; Bayet-Robert M; Gadea E; Abrial C; Thivat E; Chollet P; Eymard JC
Oncology; 2016; 90(2):69-78. PubMed ID: 26771576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
